Tinnitus Resolution

What it is: An approach that treats tinnitus as a problem of turned-up volume inside the brain rather than a problem in the ear. What it does: When the cochlea sends less signal to the brain — from noise damage, age, or synapse loss — central auditory neurons compensate by amplifying whatever input remains, a process called increased ‘central gain.’ That over-amplification raises spontaneous firing and is widely thought to generate the phantom sound. The goal of this strategy is to identify and turn down that maladaptive gain, so the auditory system stops manufacturing a signal where none exists.

The central gain model is one of the best-supported frameworks in tinnitus neuroscience. Jos Eggermont and Larry Roberts showed that after deafferentation, neurons across the auditory pathway increase their input/output gain at multiple levels, raising spontaneous activity that correlates with the tinnitus percept. Homeostatic plasticity — the same mechanism that lets neurons maintain stable average firing rates — is thought to drive this over-compensation: when peripheral input drops, the system restores its target firing rate by amplifying, and that restored activity becomes pathological hyperactivity. Computational and animal models have reproduced how hearing loss leads to homeostatic upregulation and tinnitus-like hyperactivity, and human studies link the percept to elevated central excitability. The mechanism is robust; what remains in development are interventions that selectively normalize gain without harming normal hearing — which is why this is staged as emerging rather than clinic-ready.

The central gain model is the field’s organizing framework. Jos Eggermont (University of Calgary) and Larry Roberts (McMaster University) showed through electrophysiology and review synthesis that after deafferentation, neurons across the auditory pathway raise their input/output gain, lifting spontaneous firing that correlates with the tinnitus percept.

Homeostatic plasticity drives the over-compensation. Investigators at the University of Pittsburgh and University of Michigan Kresge Hearing Research Institute used animal models of hearing loss to show that neurons restoring their target firing rate after input loss generate the pathological hyperactivity linked to tinnitus.

Computational models reproduce the chain from input loss to ringing. Modeling groups including teams at the University of Nottingham Hearing Sciences and University of Oldenburg simulated how reduced peripheral input triggers compensatory central gain and tinnitus-like hyperactivity, matching observed neurophysiology.

Human imaging ties the percept to elevated excitability. Neuroimaging and MR-spectroscopy work at Massachusetts Eye and Ear / Harvard Medical School and the University of Texas at Dallas Callier Center associated tinnitus with raised central excitability and altered auditory-cortex neurochemistry.

The trigger is consistent across tinnitus origins. Researchers at the U.S. Department of Veterans Affairs NCRAR and Karolinska Institutet found decreased peripheral input as the common upstream driver across noise-, age-, and synaptopathy-related tinnitus.

The framework directly motivates the downstream repair strategies. The gain model articulated by Eggermont and Roberts is what frames the input-restoration and inhibition-repair approaches tested in later cards, giving them a shared mechanistic target.

Research & institutions: Jos Eggermont (University of Calgary), Larry Roberts (McMaster University), University of Michigan Kresge Hearing Research Institute, University of Pittsburgh, Massachusetts Eye and Ear / Harvard Medical School, University of Texas at Dallas Callier Center, University of Nottingham Hearing Sciences, Karolinska Institutet, University of Oldenburg, U.S. Department of Veterans Affairs National Center for Rehabilitative Auditory Research (NCRAR).

What it is: A strategy aimed at the root of most tinnitus: the lost or damaged connection between the ear and the brain. What it does: Rather than only quieting the brain’s response, this approach restores the peripheral input whose absence triggered the central over-amplification in the first place. That means repairing the cochlea’s output — regenerating the ribbon synapses that link inner hair cells to the auditory nerve (often lost in ‘hidden hearing loss’) and, ultimately, the hair cells and nerve fibers themselves. Give the brain its missing signal back, and the compensatory hyperactivity that produces tinnitus has reason to stand down.

Cochlear synaptopathy — the loss of ribbon synapses between inner hair cells and spiral ganglion neurons — is an early, ‘hidden’ form of cochlear damage that can occur before any threshold shift on a standard audiogram. Loss of auditory nerve fibers has been documented in people with tinnitus, alongside brainstem hyperactivity, tying peripheral deafferentation directly to the central gain mechanism. The encouraging biology is that this damage is partly reversible: in noise-exposed animals, an antibody against the repulsive guidance molecule RGMa regenerated inner-hair-cell synapses and restored auditory-brainstem-response wave-I amplitude, and neurotrophin-based approaches aim to coax surviving nerve fibers to reconnect. This capability is staged emerging because synaptic and hair-cell regeneration are advancing rapidly in the lab and early translation, but tinnitus-specific human proof that restoring input resolves the percept is still being built.

Cochlear synaptopathy is the established ‘hidden’ first injury. Sharon Kujawa and Charles Liberman (Massachusetts Eye and Ear / Harvard Medical School) used noise-exposure models and temporal-bone histology to show ribbon synapses between inner hair cells and the auditory nerve are lost before any audiogram threshold shift.

Nerve-fiber loss is seen directly in people with tinnitus. Histopathology and physiology work from the Massachusetts Eye and Ear / Harvard Medical School group documented reduced auditory nerve fibers alongside brainstem hyperactivity, tying peripheral deafferentation to the central gain mechanism.

Synapses can be regenerated in damaged ears. Gabriel Corfas and colleagues at the University of Michigan Kresge Hearing Research Institute showed an antibody against the repulsive guidance molecule RGMa regenerated inner-hair-cell synapses and recovered auditory-brainstem-response wave-I amplitude in noise-exposed animals.

Neurotrophin strategies reconnect hair cells to nerve. Albert Edge (Massachusetts Eye and Ear / Harvard Medical School) and biotech programs at Decibel Therapeutics and Frequency Therapeutics re-established hair-cell–to–nerve connections in preclinical models, advancing toward translation.

Restoring input is the mechanistic counterpart to central gain. Work at the Stanford Initiative to Cure Hearing Loss and the Hearing Health Foundation Hearing Restoration Project frames input restoration as removing the very deafferentation that the gain model says drives the percept.

Noise-induced damage is partly self-repairing. NIH/NIDCD-funded studies and the Karolinska Institutet group demonstrated partial reversibility of noise-induced synaptopathy through endogenous repair, supporting the regeneration premise.

Research & institutions: Massachusetts Eye and Ear / Harvard Medical School (Charles Liberman, Sharon Kujawa, Gabriel Corfas, Albert Edge), Decibel Therapeutics, Frequency Therapeutics, Stanford University, Stanford Initiative to Cure Hearing Loss, University of Michigan Kresge Hearing Research Institute, Hearing Health Foundation Hearing Restoration Project, House Institute, University of Sheffield, NIH/NIDCD, Karolinska Institutet.

What it is: A therapy that uses the brain’s natural learning rules to un-train the ringing. What it does: It pairs precisely timed sound with gentle electrical pulses to the body — the cheek, neck, or tongue — in a specific sequence. Because auditory and body-sensation signals converge in the same brainstem nucleus, this timed pairing drives stimulus-timing-dependent plasticity: it nudges the synapses of the cells that generate tinnitus back toward normal, desynchronizing the maladaptive firing. The device delivers the pairing; the actual repair is the brain rewiring itself.

Susan Shore’s lab at the University of Michigan demonstrated the principle directly. In Science Translational Medicine in 2018, auditory-somatosensory bimodal stimulation desynchronized brain circuitry and reduced tinnitus in both guinea pigs and humans; in a double-blind, sham-controlled crossover study, the take-home device — calibrated to each person’s tinnitus pitch and loudness — lowered perceived tinnitus loudness compared with sound alone. The mechanism is a ‘reset’ of fusiform cells in the dorsal cochlear nucleus via stimulus-timing-dependent plasticity. A larger 2023 randomized, double-blind clinical trial in patients with somatic tinnitus reinforced meaningful benefit for that subgroup. Honest staging matters: effects are real but partial, vary by person, work best for specific subtypes, and the device was not yet FDA-cleared as of early 2026. This is genuine clinical-stage progress — not a finished universal cure.

Bimodal stimulation desynchronized the ringing in animals and humans. Susan Shore’s lab at the University of Michigan Kresge Hearing Research Institute reported in Science Translational Medicine (2018) that auditory-somatosensory bimodal stimulation desynchronized auditory circuitry and reduced tinnitus in both guinea pigs and human participants.

A blinded crossover trial showed reduced loudness. In Shore’s double-blind, sham-controlled crossover study, a take-home device calibrated to each person’s tinnitus pitch and loudness lowered perceived tinnitus loudness versus sound-only control.

A larger 2023 RCT confirmed benefit in somatic tinnitus. Shore and the University of Michigan Department of Otolaryngology ran a randomized, double-blind clinical trial that reinforced meaningful benefit for the somatic-tinnitus subgroup.

The mechanism is stimulus-timing-dependent plasticity. The Shore lab identified the effect as a ‘reset’ of fusiform cells in the dorsal cochlear nucleus via stimulus-timing-dependent plasticity, the same Hebbian rule seen in the brainstem.

Personalization is required for the effect. The Michigan protocol, now carried forward by the spinout Auricle Inc., depends on calibrating the paired stimulus to each patient’s tinnitus pitch and loudness rather than a fixed signal.

Honest staging on the device’s readiness. As characterized by the NIDCD/NIH-supported Shore program, benefit is partial and subtype-dependent and the device was not FDA-cleared as of early 2026 — genuine clinical-stage progress, not a finished universal cure.

Research & institutions: Susan Shore (University of Michigan Kresge Hearing Research Institute), University of Michigan Department of Otolaryngology, Auricle Inc. (Michigan spinout), National Institute on Deafness and Other Communication Disorders (NIDCD/NIH), University of Pittsburgh, Massachusetts Eye and Ear / Harvard Medical School, University of Nottingham Hearing Sciences, U.S. Department of Veterans Affairs NCRAR, American Tinnitus Association, University of Calgary.

What it is: A strategy targeting the ‘brakes’ of the auditory system. What it does: Healthy hearing depends on inhibitory signaling — chiefly the neurotransmitters GABA and glycine — that keeps neurons from firing too much. After hearing loss, this inhibition weakens across the auditory pathway, from the brainstem to the cortex, leaving neurons hyperexcitable and prone to the runaway firing that underlies tinnitus. This approach aims to restore that inhibitory tone — rebuilding the brakes — so auditory circuits regain their normal balance and stop over-firing into a phantom sound.

The loss-of-inhibition account is strongly supported across species and methods. Mice with behavioral evidence of tinnitus show dorsal-cochlear-nucleus hyperactivity caused specifically by decreased GABAergic inhibition (PNAS). Studies document altered GABA-A receptor subunits in the DCN and inferior colliculus, and human magnetic-resonance-spectroscopy work has found lower GABA and glutamate levels in the auditory cortex of tinnitus patients, with cortical neurochemistry tracking the presence and severity of the percept. Together these point to reduced glycinergic and GABAergic inhibition producing hyperexcitability throughout the auditory hierarchy. This is staged as frontier because the mechanism is compelling and well replicated, but restoring inhibition safely and selectively in humans — without sedation or off-target effects — remains a hard, largely preclinical pharmacological challenge.

Tinnitus hyperactivity traces to lost GABAergic inhibition. Thanos Tzounopoulos (University of Pittsburgh) showed in PNAS that mice with behavioral evidence of tinnitus have dorsal-cochlear-nucleus hyperactivity caused specifically by decreased GABAergic inhibition.

Inhibitory receptors are remodeled after hearing loss. Richard Salvi and the University at Buffalo Center for Hearing and Deafness documented altered GABA-A receptor subunits in the dorsal cochlear nucleus and inferior colliculus of tinnitus models.

Human auditory cortex shows depleted inhibitory neurochemistry. MR-spectroscopy work at the University of Nottingham Hearing Sciences and Newcastle University found lower GABA and glutamate levels in the auditory cortex of tinnitus patients.

Cortical chemistry tracks severity, not just presence. The same spectroscopy studies showed auditory-cortex neurochemistry correlating with both the presence and the severity of the percept, strengthening the causal link.

Inhibitory remodeling is system-wide. Work at the University of Leicester and University of Michigan Kresge Hearing Research Institute found enhanced tonic GABA-A inhibition in the auditory thalamus in tinnitus models, evidence of inhibitory change throughout the pathway.

Reduced glycine and GABA consistently yield hyperexcitability. Across Massachusetts Eye and Ear / Harvard Medical School, Karolinska Institutet, and University of Calgary studies, lowered glycinergic and GABAergic inhibition reliably links to hyperexcitability along the auditory hierarchy.

Research & institutions: University of Pittsburgh (Thanos Tzounopoulos), University at Buffalo Center for Hearing and Deafness (Richard Salvi), University of Michigan Kresge Hearing Research Institute, Massachusetts Eye and Ear / Harvard Medical School, University of Nottingham Hearing Sciences, Newcastle University, University of Leicester, NIH/NIDCD, Karolinska Institutet, University of Calgary.

What it is: A strategy built on a surprising fact — that body-sensation nerves can change what you hear. What it does: Signals from the jaw, neck, and head feed into the same brainstem hub that processes hearing, the dorsal cochlear nucleus. In many people this cross-talk goes wrong: tinnitus can be turned up or down by clenching the jaw, moving the neck, or pressing on the face — a subtype called somatic tinnitus. This approach targets that interaction directly, using the somatosensory channel both to identify who has it and to drive corrective plasticity in the circuits where body and sound signals meet.

Somatosensory information from the trigeminal and dorsal-root ganglia projects into the cochlear nucleus, where it can alter the spontaneous firing and synchrony of auditory neurons. In roughly 80% of tinnitus patients, head, jaw, neck, or eye movements can modulate the percept, implicating this pathway broadly. Susan Shore’s work showed that paired auditory and transcutaneous electrical stimulation of the face and neck induces stimulus-timing-dependent plasticity in dorsal-cochlear-nucleus fusiform cells — the very basis of the bimodal therapy in Card 3 — and clinical work characterizes neck and jaw dysfunction in somatosensory tinnitus. This is staged emerging: the somatosensory–auditory mechanism is well established and already informs bimodal devices, but dedicated somatic-tinnitus diagnostics and targeted treatments are still maturing toward routine clinical use.

Body-sensation nerves wire directly into the hearing hub. Susan Shore (University of Michigan Kresge Hearing Research Institute) traced somatosensory fibers from the trigeminal and dorsal-root ganglia into the cochlear nucleus, where they alter the spontaneous firing and synchrony of auditory neurons.

Most patients can physically modulate their tinnitus. Clinical studies, including work by Sarah Michiels and Annick Gilles at the University of Antwerp, found that in roughly 80% of tinnitus patients jaw, neck, head, or eye movement changes the percept — implicating this pathway broadly.

Paired stimulation induces plasticity at the convergence point. Shore’s lab showed that paired auditory and transcutaneous electrical stimulation of the face and neck drives stimulus-timing-dependent plasticity in dorsal-cochlear-nucleus fusiform cells — the basis of the bimodal therapy in Card 3.

The somatic / DCN hypothesis is established. Researchers at the University of Pittsburgh and KU Leuven formalized the craniocervical (somatic) tinnitus and dorsal-cochlear-nucleus hypothesis in the literature.

Neck and jaw dysfunction are documented clinical features. The University of Antwerp tinnitus clinic and University of Nottingham Hearing Sciences characterized neck and jaw dysfunction as identifiable features of somatosensory tinnitus, enabling diagnosis.

This cross-talk is the foundation for bimodal devices. As recognized by Tinnitus UK and the U.S. Department of Veterans Affairs NCRAR, the somatosensory–auditory interaction is the mechanistic foundation for the bimodal neuromodulation therapies now in trials.

Research & institutions: Susan Shore (University of Michigan Kresge Hearing Research Institute), University of Antwerp (Sarah Michiels, Annick Gilles), University of Pittsburgh, Massachusetts Eye and Ear / Harvard Medical School, University of Nottingham Hearing Sciences, Tinnitus UK, University of Calgary, U.S. Department of Veterans Affairs NCRAR, NIH/NIDCD, KU Leuven.

What it is: The practical delivery layer — the headphones, stimulators, apps, and protocols that bring the science of the earlier cards to actual patients. What it does: It is not a separate mechanism; it is the channel. Personalized sound therapy and bimodal neuromodulation systems administer precisely timed audio and gentle electrical stimulation, calibrated to each person’s tinnitus and adjusted over a course of daily sessions. The plasticity does the healing; this layer makes that plasticity reliable, repeatable, and usable at home — turning laboratory mechanisms into a treatment people can actually complete.

The clearest example is Lenire (Neuromod), whose bimodal approach pairs sound through headphones with mild electrical pulses delivered to the tongue via an intra-oral ‘Tonguetip.’ The TENT-A1 trial — one of the largest tinnitus trials ever run, published in Science Translational Medicine in 2020 (Conlon, Lim and colleagues) and enrolling 326 participants — reported that a large majority of compliant participants improved after 12 weeks, with most sustaining benefit at 12 months. Lenire received FDA De Novo authorization, and later real-world and clinical-practice studies reported clinically significant benefit, especially for moderate-or-worse symptoms. Staged in-clinic and honestly: these systems are delivery tools, benefit is real but partial and patient-dependent, responders are not everyone, and personalization plus adherence are essential.

One of the largest tinnitus trials ever run validated the approach. Brendan Conlon and Hubert Lim (University of Minnesota) led the TENT-A1 trial, published in Science Translational Medicine (2020) with 326 participants, reporting that a large majority of compliant users improved after 12 weeks of bimodal therapy.

Benefit was largely durable a year out. The TENT-A1 results from Neuromod Devices (Dublin) and Trinity College Dublin showed most compliant participants sustaining improvement at 12-month follow-up.

The delivery channel pairs sound with tongue stimulation. Lenire, developed by Neuromod Devices with St. James’s Hospital Dublin, pairs headphone audio with mild electrical pulses to the tongue via an intra-oral ‘Tonguetip’ as the channel for bimodal plasticity.

It cleared U.S. regulatory review. Lenire received FDA De Novo authorization for tinnitus treatment — the first such authorization for a bimodal device of its kind.

Real-world data echo the trials. Clinical-practice and chart-review studies, including work associated with the University of Regensburg Tinnitus Center, reported clinically significant benefit, especially for moderate-or-worse tinnitus.

Honest framing on what it is. As the University of Nottingham Hearing Sciences and American Tinnitus Association emphasize, this is a delivery layer rather than a mechanism — benefit is partial, varies by patient, and depends on personalization and adherence.

Research & institutions: Neuromod Devices (Dublin), Brendan Conlon and Hubert Lim (University of Minnesota), Trinity College Dublin, St. James’s Hospital Dublin, University of Regensburg / Tinnitus Center, University of Nottingham Hearing Sciences, U.S. FDA (De Novo authorization), American Tinnitus Association, Massachusetts Eye and Ear, University of Michigan.

Demonstrated components (today): human imaging and lesion evidence that a limbic–auditory “noise-cancellation” gate exists — reduced gray matter in ventromedial prefrontal cortex, altered nucleus accumbens responses, and a mapped descending pathway that can suppress the tinnitus signal. This is a mechanistic research framework that explains who develops chronic tinnitus; it is not itself a therapy and has not been turned into a proven treatment.

The capability being built toward: deliberately repairing or re-engaging this frontostriatal/limbic gate so the brain can once again cancel the phantom signal before it becomes a conscious, distressing sound — turning the model into a targeted, durable intervention.

Tinnitus often starts as a faint phantom signal generated when the auditory pathway loses input, but most people never consciously hear it — a brain “noise-cancellation” circuit quietly subtracts it out. In Rauschecker’s frontostriatal gating model, the ventromedial prefrontal cortex and nucleus accumbens (ventral striatum) act as a gatekeeper that judges a signal as irrelevant and, through descending projections, drives the thalamic reticular nucleus to clamp down thalamo-cortical transmission before the signal reaches auditory cortex. When this limbic gate is damaged or under-performs, the cancellation fails: the phantom sound leaks through to awareness and acquires emotional weight, becoming chronic and distressing. Restoring the gate — rather than only quieting the ear or the cortex — is the capability this capability points toward.

The noise-cancellation model. Josef Rauschecker and colleagues at Georgetown University Medical Center proposed (Neuron, 2010, “Tuning out the noise: limbic-auditory interactions in tinnitus”) that a tinnitus signal from auditory plasticity is normally cancelled by feedback from limbic regions, and that chronic tinnitus arises when this gate fails — a testable mechanism, not a treatment.

vmPFC gray-matter loss. Amber Leaver, Rauschecker and colleagues reported (Neuron, 2011, “Dysregulation of limbic and auditory networks in tinnitus”) reduced gray-matter volume in the ventromedial prefrontal cortex of tinnitus patients alongside altered nucleus accumbens responses at the tinnitus frequency — imaging evidence locating the gate’s control hub.

The frontostriatal gate, generalized. Rauschecker, May, Maudoux and Ploner (Trends in Cognitive Sciences, 2015, “Frontostriatal Gating of Tinnitus and Chronic Pain”) detailed how vmPFC and nucleus accumbens evaluate sensory relevance and, via descending projections to the thalamic reticular nucleus, gate thalamo-cortical transmission — positioning the TRN as the inhibitory switch the limbic gate operates.

Thalamocortical dysrhythmia. Rodolfo Llinás at NYU School of Medicine used magnetoencephalography to show that tinnitus (with neurogenic pain and other conditions) is marked by abnormal theta–gamma thalamo-cortical rhythms — independent evidence that disordered thalamus–cortex gating underlies the phantom percept.

Phantom perception as a brain network. Dirk De Ridder at the University of Otago, with collaborators, used source-localized EEG and a Bayesian-brain framework to model tinnitus as a phantom percept produced by interacting auditory and non-auditory (including limbic) subnetworks, where context-dependent perception reflects the balance of sound-transmitting and noise-canceling mechanisms.

Mapping the conscious tinnitus signal. Phillip Gander and colleagues at the University of Iowa used intracranial recordings during residual inhibition to map a distributed cortical tinnitus network, and Christo Pantev’s MEG work at the University of Münster and Winfried Schlee’s network connectivity studies show non-auditory and long-range circuits tracking the tinnitus percept — consistent with a gate that spans more than auditory cortex.

Research & institutions: Georgetown University Medical Center (Josef Rauschecker, Amber Leaver); NYU School of Medicine (Rodolfo Llinás); University of Otago, Dunedin School of Medicine (Dirk De Ridder); University of Iowa Departments of Neurosurgery & Otolaryngology (Phillip Gander); University of Münster Institute for Biomagnetism and Biosignalanalysis (Christo Pantev); University of Regensburg Department of Psychiatry and Psychotherapy (Berthold Langguth, Winfried Schlee); the Tinnitus Research Initiative; Technical University of Munich (Mark Mühlau / Markus Ploner); McMaster University (Larry Roberts); and Charité / collaborating European tinnitus imaging groups.